This is a comprehensive, 100-hour continuing education program designed to strengthen physician associates'/assistants' knowledge and clinical decision-making across a broad range of common and complex conditions affecting adult health. The curriculum integrates evidence-based approaches to cardiovascular and metabolic disease, musculoskeletal and neurologic disorders, behavioral health, pain and substance-related concerns, and ethical and end-of-life care. Topics include heart failure, hypertension, diabetes, overweight and obesity, osteoporosis, back pain, Parkinson disease, behavioral addictions, opioid safety, anabolic steroid use, medical ethics, and counseling patients and families at the end of life. The program also addresses the evidence, safety considerations, and potential drug interactions associated with natural medicines and dietary supplements used for depression, anxiety, and weight loss. Emphasizing whole-person care, this program equips physician assistants to apply current evidence and clinical principles to the assessment, management, counseling, and ongoing care of diverse adult patients.
- 1. Part I— Treatment of Heart Failure: An Update — 10 CREDITS
- 2. Part II — Hypertension: Strategies to Improve Outcomes — 5 CREDITS
- 3. Part III — Low Back Pain — 15 CREDITS
- 4. Part IV — Alternative Therapies for Depression and Anxiety — 5 CREDITS
- 5. Part V — Medical and Illicit Use of Anabolic Steroids — 5 CREDITS
- 6. Part VI — Supplements for Weight Loss — 5 CREDITS
- 7. Part VII — Type 2 Diabetes: Treatment Strategies for Optimal Care — 5 CREDITS
- 8. Part VIII — Diagnosing and Treating Overweight and Obese Patients — 5 CREDITS
- 9. Part IX — Osteoporosis: Diagnosis and Management — 5 CREDITS
- 10. Part X — Behavioral Addictions — 15 CREDITS
- 11. Part XI — Parkinson Disease — 10 CREDITS
- 12. Part XII — Counseling Patients at the End of Life — 5 CREDITS
- 13. Part XIII — Medical Ethics for Physicians — 5 CREDITS
- 14. Part XIV — Opioid Safety: Balancing Benefits and Risks — 5 CREDITS
This course is designed for physician assistants and interested healthcare professionals.
Patricia Lea, RN, DNP, MSEd, CCRN, received a Bachelor of Science degree in Nursing in 1973 from Houston Baptist University in Houston, Texas. She returned to graduate school to complete a Master’s degree in Education, specifically Health Education, in 1996 from Baylor University in Waco, Texas, and a Doctorate in Nursing Practice in Executive Leadership in 2014 from American Sentinel University in Aurora, Colorado. Dr. Lea specializes in critical care nursing, with an emphasis on heart failure and sepsis. She started her career at the Houston Methodist Hospital in the cardiovascular ICU and opened an acute dialysis unit at what is now Baylor St. Luke’s Medical Center in the Houston Medical Center. Dr. Lea was a Cardiovascular Clinical Coordinator and Director of the Heart Failure Clinic at Hillcrest Baptist Medical Center in Waco, Texas. In 2004, Dr. Lea returned to Houston and was employed as a Senior Research Clinical Nurse Specialist at the Texas Heart Institute coordinating stem cell and cardiac stent trials. She is currently Associate Professor and Baccalaureate Program Director at the University of Texas Medical Branch School of Nursing in Galveston, Texas.
John J. Whyte, MD, MPH, is currently the Chief Medical Officer at WebMD. In this role, he leads efforts to develop and expand strategic partnerships that create meaningful change around important and timely public health issues. Previously, Dr. Whyte was the Director of Professional Affairs and Stakeholder Engagement at the FDA’s Center for Drug Evaluation and Research and the Chief Medical Expert and Vice President, Health and Medical Education at Discovery Channel, part of the media conglomerate Discovery Communications.
Prior to this, Dr. Whyte was in the Immediate Office of the Director at the Agency for Healthcare Research Quality. He served as Medical Advisor/Director of the Council on Private Sector Initiatives to Improve the Safety, Security, and Quality of Healthcare. Prior to this assignment, Dr. Whyte was the Acting Director, Division of Medical Items and Devices in the Coverage and Analysis Group in the Centers for Medicare & Medicaid Services (CMS). CMS is the federal agency responsible for administering the Medicare and Medicaid programs. In his role at CMS, Dr.Whyte made recommendations as to whether or not the Medicare program should pay for certain procedures, equipment, or services. His division was responsible for durable medical equipment, orthotics/prosthetics, drugs/biologics/therapeutics, medical items, laboratory tests, and non-implantable devices. As Division Director as well as Medical Officer/Senior Advisor, Dr. Whyte was responsible for more national coverage decisions than any other CMS staff.
Dr. Whyte is a board-certified internist. He completed an internal medicine residency at Duke University Medical Center as well as earned a Master’s of Public Health (MPH) in Health Policy and Management at Harvard University School of Public Health. Prior to arriving in Washington, Dr. Whyte was a health services research fellow at Stanford and attending physician in the Department of Medicine. He has written extensively in the medical and lay press on health policy issues.
Mark Rose, BS, MA, LP, is a licensed psychologist in the State of Minnesota with a private consulting practice and a medical research analyst with a biomedical communications firm. Earlier healthcare technology assessment work led to medical device and pharmaceutical sector experience in new product development involving cancer ablative devices and pain therapeutics. Along with substantial experience in addiction research, Mr. Rose has contributed to the authorship of numerous papers on CNS, oncology, and other medical disorders. He is the lead author of papers published in peer-reviewed addiction, psychiatry, and pain medicine journals and has written books on prescription opioids and alcoholism published by the Hazelden Foundation. He also serves as an Expert Advisor and Expert Witness to law firms that represent disability claimants or criminal defendants on cases related to chronic pain, psychiatric/substance use disorders, and acute pharmacologic/toxicologic effects. Mr. Rose is on the Board of Directors of the Minneapolis-based International Institute of Anti-Aging Medicine and is a member of several professional organizations.
Chelsey McIntyre, PharmD, is a clinical pharmacist who specializes in drug information, literature analysis, and medical writing. She earned her Bachelor of Science degree in Genetics from the University of California, Davis. She then went on to complete her PharmD at Creighton University, followed by a clinical residency at the Children’s Hospital of Philadelphia (CHOP). Dr. McIntyre held the position of Drug Information and Policy Development Pharmacist at CHOP until her move to Washington state in 2017, after which she spent the next six years as a clinical editor for Natural Medicines, a clinical reference database focused on natural products and alternative therapies. She continues to create rigorous professional analysis and patient education materials for various publications while also practicing as a hospital pharmacist. Her professional interests include provider and patient education, as well as the application of evidence-based research to patient care.
Lisa Hutchison, LMHC, has more than 20 years of experience providing individual and group counseling with adults. She specifically focuses on teaching assertiveness, stress management, and boundary setting for empathic helpers. Ms. Hutchison graduated from the University of Massachusetts, Boston, with a Master’s degree in education for mental health counseling.
John M. Leonard, MD, Professor of Medicine Emeritus, Vanderbilt University School of Medicine, completed his post-graduate clinical training at the Yale and Vanderbilt University Medical Centers before joining the Vanderbilt faculty in 1974. He is a clinician-educator and for many years served as director of residency training and student educational programs for the Vanderbilt University Department of Medicine. Over a career span of 40 years, Dr. Leonard conducted an active practice of general internal medicine and an inpatient consulting practice of infectious diseases.
Contributing faculty, Patricia Lea, RN, DNP, MSEd, CCRN, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, John J. Whyte, MD, MPH, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, Mark Rose, BS, MA, LP, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, Chelsey McIntyre, PharmD, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, Lisa Hutchison, LMHC, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, John M. Leonard, MD, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
John V. Jurica, MD, MPH
John M. Leonard, MD
The division planners have disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.
Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.
Supported browsers for Windows include Microsoft Internet Explorer 9.0 and up, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Supported browsers for Macintosh include Safari, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Other operating systems and browsers that include complete implementations of ECMAScript edition 3 and CSS 2.0 may work, but are not supported. Supported browsers must utilize the TLS encryption protocol v1.1 or v1.2 in order to connect to pages that require a secured HTTPS connection. TLS v1.0 is not supported.
#41970: The Adult Patient: Evidence-Based Care for Mind and Body
Part 10 of 14 · Chapter 1 of 14
Table of Contents
- INTRODUCTION
- BEHAVIORAL ADDICTION: EVOLUTION AND CONCEPTS
- EXPLANATORY MODELS OF ADDICTION
- CHILD AND ADOLESCENT VULNERABILITY TO BEHAVIORAL ADDICTION
- OVERVIEW OF GENERAL BEHAVIORAL ADDICTION TREATMENT
- GAMBLING DISORDER
- ADDICTIVE SEXUAL BEHAVIOR
- INTERNET GAMING DISORDER
- BINGE EATING DISORDER
- COMPULSIVE BUYING DISORDER
- TRICHOTILLOMANIA (HAIR PULLING DISORDER)
- KLEPTOMANIA (COMPULSIVE STEALING)
- IATROGENIC BEHAVIORAL ADDICTIONS
- CONCLUSION
- Works Cited
The purpose of this course is to provide clinicians with the knowledge and skills to appropriately identify, diagnose, and treat behavioral addictions.
Upon completion of this course, you should be able to:
- Outline the evolution of and concepts forming the basis of behavioral addictions.
- Compare and contrast explanatory models of addiction and their applicability to behavioral addictions.
- Describe the factors underlying child and adolescent vulnerability to behavioral addictions.
- Discuss psychological and pharmacologic treatments that are generally appropriate for behavioral addiction.
- Analyze the epidemiology, comorbidity, and risk factors of gambling disorder.
- Evaluate the diagnosis and treatment of gambling disorder.
- Review the pathophysiology, diagnosis, and treatment of addictive sexual behavior.
- Describe Internet gaming disorder and how it is diagnosed and treated.
- Explain how binge eating disorder is identified and appropriately treated.
- Outline the epidemiology, risk factors, and clinical characteristics of compulsive buying disorder.
- Analyze factors related to the diagnosis and treatment of compulsive buying disorder.
- Discuss the epidemiology, comorbidities, and pathophysiology of trichotillomania.
- List approaches to the treatment of trichotillomania.
- Identify patients with kleptomania and create an effective treatment plan for these patients.
- Describe behavioral addictions induced by dopamine agonists and other medications and disorders.
The term "addiction" is traditionally used to describe the pathologic behavioral patterns a subset of persons exhibit from exposure to substances with central nervous system (CNS) activity (e.g., heroin, cocaine, alcohol). However, addiction is not a unitary construct; it incorporates common features that include repetitive engagement in rewarding (at least initially) behaviors, loss of control (spiraling engagement over time), persistence despite consequences, aversive states when ingestion is halted or substantially cut back, and an appetitive urge or craving state prior to engaging in the behavior. Many of these pathologic behaviors have long been classified as impulse control disorders, including pathologic gambling, intermittent explosive disorder, kleptomania, pyromania, and trichotillomania. Research suggests that several of these impulse control disorders more accurately represent behavioral addictions.
As a distinct area of study, behavioral addiction is recent, and extensive knowledge advances have been made since 2010. Growing evidence suggests that behavioral and substance addictions overlap in clinical expression (e.g., craving, tolerance, withdrawal symptoms), comorbidity, neurobiologic profile, heritability, and treatment. Behavioral and substance addictions also share similar features in natural history, phenomenology, and adverse consequences. This course will address the most common non-substance behavioral addictions, including pathologic gambling, compulsive sexual behavior, compulsive buying, and compulsive video gaming.
2. Blaszczynski A. Commentary on: are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research. J Behav Addict. 2015;4(3):142-144.
3. Hollander E. Obsessive-Compulsive Related Disorders. Washington, DC: American Psychiatric Press; 1993.
4. Starcevic V. Behavioural addictions: a challenge for psychopathology and psychiatric nosology. Aust N Z J Psychiatry. 2016;50(8):721-725.
5. Cuzen NL, Stein DJ. Behavioral addiction: the nexus of impulsivity and compulsivity. In: Rosenberg KP, Feder LC (eds). Behavioral Addictions: Criteria, Evidence, and Treatment. Boston, MA: Academic Press; 2014: 19-34.
6. Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006;101(Suppl 1):142-151.
7. American Society of Addiction Medicine. Definition of Addiction. Available at https://www.asam.org/quality-care/definition-of-addiction. Last accessed April 3, 2024.
8. Billieux J, Deleuze J, Griffiths MD, Kuss DJ. Internet gaming addiction: the case of massively multiplayer online role-playing games. In: Carra G, el-Guebaly N, Galanter M. (eds). Textbook of Addiction Treatment: International Perspectives. Milan: Springer-Verlag; 2015.
9. Aarseth E, Bean AM, Boonen H, et al. Scholars' open debate paper to the World Health Organization on Gaming Disorder Proposal.J Behav Addict. 2017;6(3):267-270.
10. Yücel M, Carter A, Allen AR, et al. An interdisciplinary dialogue on gambling: perspectives on the role for neuroscience in gambling policy and treatment. Lancet Psychiatry. 2017;4(6):501-506.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text revision. Washington, DC: American Psychiatric Association; 2022.
12. Taneli T, Guo Y-H, Mushtaq S. Internet gaming disorder. In: Ascher MS, Levounis P (eds). The Behavioral Addictions. Washington, DC: American Psychiatric Publishing; 2015.
13. Young KS. Internet addiction: the emergence of a new clinical disorder. Cyberpsychol Behav Soc Netw. 1996;1(3):237-244.
14. Musetti A, Cattivelli R, Giacobbi M, et al. Challenges in Internet addiction disorder: is a diagnosis feasible or not? Front Psychol. 2016;7:842.
15. Griffiths MD, Kuss DJ, Billieux J, Pontes HM. The evolution of Internet addiction: a global perspective. Addict Behav. 2016;53:193-195.
16. Griffiths MD. Social networking addiction: emerging themes and issues. J Addict Res Ther. 2013;4:5.
17. Griffiths MD, Pontes HM, Kuss DJ. Online addictions: conceptualizations, debates, and controversies. Addicta. 2016;3:1-20.
18. Griffiths MD. Internet abuse and internet addiction in the workplace. J Workplace Learning. 2010;22(7):463-472.
19. Griffiths MD. Gambling technologies: prospects for problem gambling. J Gambl Stud. 1999;15(3):265-283.
20. Starcevic V, Billieux J. Does the construct of Internet addiction reflect a single entity or a spectrum of disorders? Clin Neuropsychiatry. 2017;14(1):5-10.
23. Grant JE, Chamberlain SR. Psychopharmacological Options for Treating Impulsivity. Available at https://www.psychiatrictimes.com/view/psychopharmacological-options-treating-impulsivity. Last accessed April 3, 2024.
24. Smith JL, Mattick RP, Jamadar SD, Iredale JM. Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis. Drug Alcohol Depend. 2014;145:1-33.
25. Robertson CL. Striatal Dopamine Receptors, Inhibitory Control and Methamphetamine Use Disorder. Dissertation. Los Angeles, CA; 2015.
26. Choi JS, Shin YC, Jung WH, et al. Altered brain activity during reward anticipation in pathological gambling and obsessive-compulsive disorder. PLoS One. 2012;7(9):e45938.
27. Stein DJ, Hollander E. Obsessive-compulsive spectrum disorders. J Clin Psychiatry. 1995;56(6):265-266.
28. Acton GS. Measurement of impulsivity in a hierarchical model of personality traits: implications for substance use. Subst Use Misuse. 2003;38(1):67-83.
29. Grant JE, Kim SW. Brain circuitry of compulsivity and impulsivity. CNS Spectr. 2014;19(1):21-27.
30. Wrase J, Kahnt T, Schlagenhauf F, et al. Different neural systems adjust motor behavior in response to reward and punishment. Neuroimage. 2007;36(4):1253-1262.
31. Fineberg NA, Chamberlain SR, Goudriaan AE, et al. New developments in human neurocognition: clinical, genetic and brain imaging correlates of impulsivity and compulsivity. CNS Spectr. 2014;19(1):69-89.
32. Guo Z, Liang S, Ren L, et al. Applying network analysis to understand the relationships between impulsivity and social media addiction and between impulsivity and problematic smartphone use. Front Psychiatry. 2022;13:993328.
33. Petry NM. Delay discounting of money and alcohol in actively using alcoholics, currently abstinent alcoholics, and controls. Psychopharmacology (Berl). 2001;154(3):243-250.
34. Petry NM. Patterns and correlates of Gamblers Anonymous attendance in pathological gamblers seeking professional treatment.Addict Behav. 2003;28(6):1049-1062.
35. Perry JL, Carroll ME. The role of impulsive behavior in drug abuse. Psychopharmacology (Berl). 2008;200(1):1-26.
36. Clark L, Robbins TW, Ersche KD, Sahakian BJ. Reflection impulsivity in current and former substance users. Biol Psychiatry. 2006;60(5):515-522.
37. Weinstein A, Abu Hodaya B, Timor A, Mama Y. Delay discounting, risk-taking, and rejection sensitivity among individuals with Internet and video gaming disorders. J Addict Behav. 2016;5(4):674-682.
38. de Wit H. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol. 2009;14(1):22-31.
39. Groman SM, Jentsch JD. Identifying the molecular basis of inhibitory control deficits in addictions: neuroimaging in non-human primates. Curr Opin Neurobiol. 2013;23(4):625-631.
40. Volkow ND, Koob G, Baler R. Biomarkers in substance use disorders. ACS Chem Neurosci. 2015;6(4):522-525.
41. Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron. 2011;69(4):680-694.
42. Fineberg NA, Potenza MN, Chamberlain SR, et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology. 2010;35(3):591-604.
43. Banca P, Harrison NA, Voon V. Compulsivity across the pathological misuse of drug and non-drug rewards. Front Behav Neurosci. 2016;10:154.
44. Potenza MN. Biological contributions to addictions in adolescents and adults: prevention, treatment and policy implications.J Adolesc Health. 2013;52(2 Suppl 2):S22-S32.
45. Koob GF. Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder.Curr Top Behav Neurosci. 2013;13:3-30.
46. Mestre-Bach G, Granero R, Steward T, et al. Reward and punishment sensitivity in women with gambling disorder or compulsive buying: implications in treatment outcome. J Addict Behav. 2016;5:658-665.
47. Gray J, McNaughton N. The Neuropsychology of Anxiety: An Enquiry Into the Functions of the Septo-Hippocampal System. 2nd ed. Oxford: Oxford University Press; 2008.
49. Zeinali A, Sharifi H, Enayati M, Asgari P, Pasha G. The mediational pathway among parenting styles, attachment styles and self-regulation with addiction susceptibility of adolescents. J Res Med Sci. 2011;16(9):1105-1121.
50. Jia R, Jia HH. Maybe you should blame your parents: parental attachment, gender, and problematic Internet use. J Addict Behav. 2016;5(3):524-528.
51. Noftle EE, Shaver PR. Attachment dimensions and the big five personality traits: associations and comparative ability to predict relationship quality. J Res Personality. 2006;40(2):179-208.
52. Chang FC, Chiu CH, Miao NF, et al. The relationship between parental mediation and Internet addiction among adolescents, and the association with cyberbullying and depression. Compr Psychiatry. 2015;57:21-28.
53. Jenkins-Guarnieri MA, Wright SL, Hudiburgh L. The relationships among attachment style, personality traits, interpersonal competency, and Facebook use. J Appl Dev Psychol. 2012;33(6):294-301.
54. Dong G, Potenza MN. A cognitive-behavioral model of Internet gaming disorder: theoretical underpinnings and clinical implications.J Psychiatr Res. 2014;58:7-11.
55. Griffiths MD. A "components" model of addiction within a biopsychosocial framework. J Subst Use. 2005;10(4):191-197.
56. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.Nat Rev Neurosci. 2011;12(11):652-669.
57. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013;64:452-463.
58. Dong G, Hu Y, Lin X, Lu Q. What makes Internet addicts continue playing online even when faced by severe negative consequences? Possible explanations from an fMRI study. Biol Psychol. 2013;94(2):282-289.
59. Potenza MN. Non-substance addictive behaviors in the context of DSM-5. Addict Behav. 2014;39(1):1-2.
60. Brand M, Young KS, Laier C, Wölfling K, Potenza MN. Integrating psychological and neurobiological considerations regarding the development and maintenance of specific Internet-use disorders: an Interaction of Person-Affect-Cognition-Execution (I-PACE) model. Neurosci Biobehav Rev. 2016;71:252-266.
61. Kor A, Zilcha-Mano S, Fogel YA, Mikulincer M, Reid RC, Potenza MN. Psychometric development of the problematic pornography use scale. Addict Behav. 2014;39(5):861-886.
62. Lam LT, Wong EM. Stress moderates the relationship between problematic internet use by parents and problematic Internet use by adolescents. J Adolesc Health. 2015;56(3):300-306.
63. Zhang J-T, Yao Y-W, Potenza MN, et al. Effects of craving behavioral intervention on neural substrates of cue-induced craving in Internet gaming disorder. Neuroimage Clin. 2016;12:591-599.
64. Odaci H, Kalkan M. Problematic Internet use: loneliness and dating anxiety among young adult university students. Comput Educ. 2010;55(3):1091-1097.
65. Pontes HM, Griffiths MD, Patrão IM. Internet addiction and loneliness among children and adolescents in the education setting: an empirical pilot study. Aloma. 2014;32(1):91-98.
67. Iacono WG, Malone SM, McGue M. Behavioral disinhibition and the development of early-onset addiction: common and specific influences. Annu Rev Clin Psychol. 2008;4:325-348.
68. Galvan A, Hare TA, Parra CE, et al. Earlier development of the accumbens relative to orbitofrontal cortex might underlie risk-taking behavior in adolescents. J Neurosci. 2006;26(25):6885-6892.
69. Ernst M, Fudge JL. A developmental neurobiological model of motivated behavior: anatomy, connectivity and ontogeny of the triadic nodes. Neurosci Biobehav Rev. 2009;33(3):367-382.
70. Dahl RE. Biological, developmental, and neurobehavioral factors relevant to adolescent driving risks. Am J Prev Med. 2008;35 (3 Suppl):S278-S284.
71. Smith DP, Dunn KI, Harvey PW, Battersby MW, Pols RG. Assessing randomised clinical trials of cognitive and exposure therapies for gambling disorders: a systematic review. Behaviour Change. 2013;30(3):139158.
72. Carroll KM, Kiluk BD, Nich C, et al. Cognitive function and treatment response in a randomized clinical trial of computer-based training in cognitive-behavioral therapy. Subst Use Misuse. 2011;46(1):23-34.
73. DeVito E, Worhunsky P, Carroll K, Rounsaville BJ, Kober H, Potenza MN. A preliminary study of the neural effects of behavioral therapy for substance use disorders. Drug Alcohol Depend. 2012;122(3):228-235.
75. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005;162(8):1452-1460.
76. Cohen LJ. Sex addiction. In: Ascher MS, Levounis P (eds). The Behavioral Addictions. Washington, DC: American Psychiatric Publishing; 2015.
77. Grilo CM, White MA, Gueorguieva R, Barnes RD, Masheb RM. Self-help for binge eating disorder in primary care: a randomized controlled trial with ethnically and racially diverse obese patients. Behav Res Ther. 2013;51(12):855-861.
78. Bickel WK, Yi R, Landes RD, Hill PF, Baxter C. Remember the future: working memory training decreases delay discounting among stimulant addicts. Biol Psychiatry. 2011;69(3):260-265.
79. Zhou Z, Yuan G, Yao J. Cognitive biases toward Internet game-related pictures and executive deficits in individuals with an Internet game addiction. PLoS One. 2012;7(11):e48961.
80. Witkiewitz K, Lustyk MK, Bowen S. Retraining the addicted brain: a review of hypothesized neurobiological mechanisms of mindfulness-based relapse prevention. Psychol Addict Behav. 2013;27(2):351-365.
81. Berkman ND, Brownley KA, Peat CM, et al. Management and Outcomes of Binge-Eating Disorder. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
82. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York, NY: Guilford; 2002.
84. Potenza MN, Balodis IM, Franco CA, et al. Neurobiological considerations in understanding behavioral treatments for pathological gambling. Psychol Addict Behav. 2013;27(2):380-392.
85. Grant JE, Chamberlain SR. Pharmacotherapy for behavioral addictions. Curr Behav Neurosci Rep. 2016;3(1):67-72.
86. Inagaki TK, Ray LA, Irwin MR, Way BM, Eisenberger NI. Opioids and social bonding: naltrexone reduces feelings of social connection. Soc Cogn Affect Neurosci. 2016;11(5):728-735.
87. Inagaki TK, Hazlett LI, Andreescu C. Opioids and social bonding: effect of naltrexone on feelings of social connection and ventral striatum activity to close others. J Exp Psychol Gen. 2020;149(4):732-745.
88. Auer MM, Griffiths MD. Personalized behavioral feedback for online gamblers: a real world empirical study. Front Psychol. 2016;7:1875.
89. Griffiths MD. Problem gambling and gambling addiction are not the same. J Addict Depend. 2016;2(1):1-3.
90. Loo JMY, Kraus SW, Potenza MN. A systematic review of gambling-related findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Behav Addict. 2019;8(4):625-648.
91. Grant JE, Odlaug BL, Mooney ME. Telescoping phenomenon in pathological gambling: association with gender and comorbidities.J Nerv Ment Dis. 2012;200(11):996-998.
92. Calado F, Griffiths MD. Problem gambling worldwide: an update and systematic review of empirical research (2000–2015). J Behav Addict. 2016;5(4):592-613.
93. Oei TP, Gordon LM. Psychosocial factors related to gambling abstinence and relapse in members of gamblers anonymous. J Gambl Stud. 2008;24(1):91-105.
94. Nower L, Martins SS, Lin KH, Blanco C. Subtypes of disordered gamblers: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addiction. 2013;108(4):789-798.
95. Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(5):564-574.
96. Blaszczynski A, Russell A, Gainsbury S, Hing N. Mental health and online, land-based and mixed gamblers. J Gambl Stud. 2016;32(1):261-275.
97. Gainsbury SM. Online gambling addiction: the relationship between Internet gambling and disordered gambling. Curr Addict Rep. 2015;2(2):185-193.
98. Sanacora RL, Whiting SW, Pilver CE, Hoff RA, Potenza MN. Relationships between problem-gambling severity and psychopathology as moderated by income. J Behav Addict. 2016;5(3):429-438.
99. Clark L, Lawrence AJ, Astley-Jones F, Gray N. Gambling near-misses enhance motivation to gamble and recruit win-related brain circuitry. Neuron. 2009;61(3):481-490.
100. Dowling N, Smith D, Thomas T. Electronic gaming machines: are they the "crack cocaine" of gambling? Addiction. 2005;100(1):33-45.
101. Petry NM, Oncken C. Cigarette smoking is associated with increased severity of gambling problems in treatment-seeking gamblers. Addiction. 2002;97(6):745-753.
102. Grant JE, Kim SW, Odlaug BL, Potenza MN. Daily tobacco smoking in treatment-seeking pathological gamblers: clinical correlates and co-occurring psychiatric disorders. J Addict Med. 2008;2(4):178-184.
103. Weinberger AH, Franco CA, Hoff RA, et al. Cigarette smoking, problem-gambling severity, and health behaviors in high-school students. Addict Behav Rep. 2015;1:40-48.
104. Grant JE, Derbyshire K, Leppink E, Chamberlain SR. Suicidality in non-treatment seeking young adults with subsyndromal gambling disorder. Psychiatr Q. 2014;85(4):513-522.
105. Quintero GC. A biopsychological review of gambling disorder. Neuropsychiatr Dis Treat. 2017;13:51-60.
106. Grant JE, Odlaug BL, Chamberlain SR. Neural and psychological underpinnings of gambling disorder: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:188-193.
107. Limbrick-Oldfield EH, Mick I, Cocks RE, et al. Neural substrates of cue reactivity and craving in gambling disorder. Translational Psychiatry. 2017;7:e992.
108. Granero R, Penelo E, Stinchfield R, et al. Is pathological gambling moderated by age? J Gambl Stud. 2014;30(2)475-492.
109. World Health Organization. The 11th Revision of the International Classification of Diseases (ICD-11). Available at https://icd.who.int/browse11/l-m/en. Last April 3, 2024.
110. Choi S-W, Shin Y-C, Youn HC, Lim S-W, Ha J. Pharmacotherapy and group cognitive behavioral therapy enhance follow-up treatment duration in gambling disorder patients. Ann Gen Psychiatry. 2016;15:20.
111. Suurvali H, Cordingley J, Hodgins DC, Cunningham J. Barriers to seeking help for gambling problems: a review of the empirical literature. J Gambl Stud. 2009;25(3):407-424.
112. Turner N, Zangeneh M, Littman-Sharp N. The experience of gambling and its role in problem gambling. Int Gamb Stud. 2006;6(2):237-266.
113. Rash CJ, Petry NM. Gambling disorder. In: Ascher MS, Levounis P (eds). The Behavioral Addictions. Washington, DC: American Psychiatric Publishing; 2015.
114. Petry NM, Ammerman Y, Bohl J, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol. 2006;74(3):555-567.
115. Pallesen S, Mitsem M, Kvale G, Johnsen BH, Molde H. Outcome of psychological treatments of pathological gambling: a review and meta-analysis. Addiction. 2005;100(10):1412-1422.
116. Ladouceur R, Sylvain C, Boutin C, et al. Cognitive treatment of pathological gambling. J Nerv Ment Dis. 2001;189(11):774-780.
117. Larimer ME, Neighbors C, Lostutter TW, et al. Brief motivational feedback and cognitive behavioral interventions for prevention of disordered gambling: a randomized clinical trial. Addiction. 2012;107(6):1148-1158.
118. Pfund RA, Forman DP, Whalen SK, et al. Effect of cognitive-behavioral techniques for problem gambling and gambling disorder: a systematic review and meta-analysis. Addiction. 2023;118(9):1661-1674.
119. Potenza MN, Sofuoglu M, Carroll KM, Rounsaville BJ. Neuroscience of behavioral and pharmacological treatments for addictions. Neuron. 2011;69(4):695-712.
120. Petry NM. Gamblers anonymous and cognitive-behavioral therapies for pathological gamblers. J Gambl Stud. 2005;21(1):27-33.
121. Hodgins DC, Currie SR, el-Guebaly N. Motivational enhancement and self-help treatments for problem gambling. J Consult Clin Psychol. 2001;69(1):50-57.
122. Petry NM, Weinstock J, Morasco BJ, Ledgerwood DM. Brief motivational interventions for college student problem gamblers. Addiction. 2009;104(9):1569-1578.
123. Rash CJ, Weinstock J, Petry NM. Drinking patterns of pathological gamblers before, during, and after gambling treatment. Psychol Addict Behav. 2011;25(4):664-674.
124. Lister JJ, Milosevic A, Ledgerwood DM. Personality traits of problem gamblers with and without alcohol dependence. Addict Behav. 2015;47:48-54.
125. Josephson H, Carlbring P, Forsberg L, Rosendahl I. People with gambling disorder and risky alcohol habits benefit more from motivational interviewing than from cognitive behavioral group therapy. Peer J. 2016;4:e1899.
126. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914-921.
127. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of pathological gambling urges. J Clin Psychiatry. 2009;69(5):783-789.
128. Kovanen L, Basnet S, Castrén S, et al. A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016;22(2):70-79.
129. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303-312.
130. Grant JE, Odlaug BL, Potenza MN, et al. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010;197(4):330-331.
131. Grant JE, Potenza MN, Hollander E, et al. A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303-312.
132. Grant JE, Odlaug BL, Chamberlain SR, Hampshire A, Schreiber LR, Kim SW. A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol. 2013;23(11):1587-1596.
133. Grant JE, Derbyshire K, Leppink E, Chamberlain SR. One-year follow-up of subsyndromal gambling disorder in non-treatment-seeking young adults. Ann Clin Psychiatry. 2014;26(3):199-205.
134. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62(6):652-657.
135. Grant JE, Odlaug BL, Chamberlain SR, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014;75(1):39-45.
136. Schuler A, Ferentzy P, Turner NE, et al. Gamblers Anonymous as a recovery pathway: a scoping review. J Gambl Stud. 2016;32(4):1261-1278.
137. Garcia FD, Assumpção AA, Malloy-diniz L, De Freitas AAC, Delavenne H, Thibaut F. A comprehensive review of psychotherapeutic treatment of sexual addiction. J Groups Addict Recovery. 2016;11(1):59-71.
138. Cantor JM, Klein C, Lykins A, Rullo JE, Thaler L, Walling BR. A treatment-oriented typology of self-identified hypersexuality referrals. Arch Sex Behav. 2013;42(5):883-893.
139. Yoon IS, Houang ST, Hirshfield S, Downing MJ Jr. Compulsive sexual behavior and HIV/STI risk: a review of current literature.Curr Addict Rep. 2016;3(4):387-399.
140. Derbyshire KL, Grant JE. Compulsive sexual behavior: a review of the literature. J Behav Addict. 2015;4(2):37-43.
141. Carabajal CE. Location-Based Heartbreak: The Privacy of Dating Application Users is at Risk. Available at https://ripl.law.uic.edu/news-stories/location-based-heartbreak-the-privacy-of-dating-application-users-is-at-risk/. Last accessed April 3, 2024.
142. Grant JE, Schreiber LRN, Odlaug BL. Phenomenology and treatment of behavioural addictions. Can J Psychiatry. 2013;58(5):252-259.
143. Coleman E. Is your patient suffering from compulsive sexual behavior? Psychiatr Ann. 1992;22(6):320-325.
144. Kafka MP, Prentky RA. A comparative study of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry. 1992;53(10):345-350.
145. Schreiber LRN, Odlaug BL, Grant JE. Compulsive sexual behavior: phenomenology and epidemiology. In: Grant JE, Potenza MN (eds). The Oxford Handbook of Impulse Control Disorders. Oxford: Oxford University Press; 2012:165-175.
146. Black DW, Kerhberg LLD, Flumerfelt DL, Schlosser SS. Characteristics of 36 subjects reporting compulsive sexual behavior.Am J Psychiatry. 1997;154(2):243-249.
147. Farré JM, Fernández-Aranda F, Granero R, et al. Sex addiction and gambling disorder: similarities and differences. Compr Psychiatry. 2015;56:59-68.
148. Laier C, Pekal J, Brand M. Cybersex addiction in heterosexual female users of Internet pornography can be explained by gratification hypothesis. Cyberpsychol Behav Soc Netw. 2014;17(8):505-511.
149. Blais-Lecours S, Vaillancourt-Morel MP, Sabourin S, Godbout N. Cyberpornography: time use, perceived addiction, sexual functioning, and sexual satisfaction. Cyberpsychol Behav Soc Netw. 2016;19(11):649-655.
150. Sumter SR, Vandenbosch L. Dating gone mobile: demographic and personality-based correlates of using smartphone-based dating applications among emerging adults. New Media Society. 2019;21(3):655-673.
151. Park BY, Wilson G, Berger J, et al. Is Internet pornography causing sexual dysfunctions? A review with clinical reports. Behav Sci (Basel). 2016;6(3):E17.
152. Armed Forces Health Surveillance Center. Erectile dysfunction among male active component service members, U.S. Armed Forces, 2004–2013. MSMR. 2014;21(9):13-16.
153. O'Sullivan LF, Brotto LA, Byers ES, et al. Prevalence and characteristics of sexual functioning among sexually experienced middle to late adolescents. J Sex Med. 2014;11(3):630-641.
154. O'Sullivan LF, Byers ES, Brotto LA, Majerovich JA, Fletcher J. A longitudinal study of problems in sexual functioning and related sexual distress among middle to late adolescents. J Adolesc Health. 2016;59(3):318-324.
155. Klein V, Jurin T, Briken P, Štulhofer A. Erectile dysfunction, boredom, and hypersexuality among coupled men from two European countries. J Sex Med. 2015;12(11):2160-2167.
156. Martins FG, Abdo CHN. Erectile dysfunction and correlated factors in Brazilian men aged 18–40 years. J Sex Med. 2010;7(6):2166-2173.
157. Papagiannopoulos D, Khare N, Nehra A. Evaluation of young men with organic erectile dysfunction. Asian J Androl. 2015;17(1):11-16.
158. Meerkerk GJ, Van Den Eijnden RJJM, Garretsen HFL. Predicting compulsive Internet use: it's all about sex! Cyberpsychol Behav. 2006;9(1):95-103.
159. Voon V, Mole TB, Banca P, et al. Neural correlates of sexual cue reactivity in individuals with and without compulsive sexual behaviours. PLoS One. 2014;9(7):e102419.
160. Arnow BA, Desmond JE, Banner LL, et al. Brain activation and sexual arousal in healthy, heterosexual males. Brain. 2002;125 (Pt 5):1014-1023.
161. Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev. 2007;56(2):283-321.
162. Hilton DL. Pornography addiction a supranormal stimulus considered in the context of neuroplasticity. Socioaffect Neurosci Psychol. 2013;3:20767.
163. Negash S, Sheppard NV, Lambert NM, Fincham FD. Trading later rewards for current pleasure: pornography consumption and delay discounting. J Sex Res. 2016;53(6):689-700.
164. Schomaker J, Meeter M. Short- and long-lasting consequences of novelty, deviance and surprise on brain and cognition. Neurosci Biobehav Rev. 2015;55:268-279.
165. Pitchers KK, Vialou V, Nestler EJ, Laviolette SR, Lehman MN, Coolen LM. Natural and drug rewards act on common neural plasticity mechanisms with DeltaFosB as a key mediator. J Neurosci. 2013;33(8):3434-3442.
166. Feil J, Sheppard D, Fitzgerald PB, Yücel M, Lubman DI, Bradshaw JL. Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Neurosci Biobehav Rev. 2010;35(2):248-275.
167. Schiebener J, Laier C, Brand M. Getting stuck with pornography? Overuse or neglect of cybersex cues in a multitasking situation is related to symptoms of cybersex addiction. J Behav Addict. 2015;4(1):14-21.
168. Brand M, Laier C, Pawlikowski M, Schächtle U, Schöler T, Altstötter-Gleich C. Watching pornographic pictures on the Internet: role of sexual arousal ratings and psychological-psychiatric symptoms for using Internet sex sites excessively. Cyberpsychol Behav Soc Netw. 2011;14(6):371-377.
169. Janssen E, Bancroft J. The dual-control model: the role of sexual inhibition and excitation in sexual arousal and behavior. In: Janssen E (ed). The Psychophysiology of Sex. Bloomington IN: Indiana University Press; 2007.
170. Park JH, Lee YS, Sohn JH, Han DH. Effectiveness of atomoxetine and methylphenidate for problematic online gaming in adolescents with attention deficit hyperactivity disorder. Hum Psychopharmacol. 2016;31(6):427-432.
171. Zillmann D, Bryant J. Pornography's impact on sexual satisfaction. J Appl Soc Psychol. 2006;18(5):438-453.
172. Song H, Zou Z, Kou J, et al. Love-related changes in the brain: a resting-state functional magnetic resonance imaging study. Front Hum Neurosci. 2015;9:71.
173. Ferris CF, Snowdon CT, King JA, et al. Activation of neural pathways associated with sexual arousal in non-human primates. J Magn Reson Imaging. 2004;19(2):168-175.
174. Kühn S, Gallinat J. Brain structure and functional connectivity associated with pornography consumption: the brain on porn. JAMA Psychiatry. 2014;71(7):827-834.
175. Sun C, Miezan E, Lee N-Y, Shim JW. Korean men's pornography use, their interest in extreme pornography, and dyadic sexual relationships. Int J Sex Health. 2015;27:16-35.
176. Sun C, Bridges A, Johnson J, Ezzell M. Pornography and the male sexual script: an analysis of consumption and sexual relations.Arch Sex Behav. 2014;45(4):1-12.
177. Pfaus JG, Kippin TE, Coria-Avila GA, et al. Who, what, where, when (and maybe even why)? How the experience of sexual reward connects sexual desire, preference, and performance. Arch Sex Behav. 2012;41(1):31-62.
178. Billieux J, Schimmenti A, Khazaal Y, Marage P, Heeren A. Are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research. J Behav Addict. 2015;4(3):119-123.
179. Callesen MB, Weintraub D, Damholdt MF, Møller A. Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. Parkinsonism Relat Disord. 2014;20(1):22-26.
180. Cooper CA, Jadidian A, Paggi M, et al. Prevalence of hypersexual behavior in Parkinson's disease patients: not restricted to males and dopamine agonist use. Int J Gen Med. 2009;2:57-61.
181. Krueger RB. Diagnosis of hypersexual or compulsive sexual behavior can be made using ICD-10 and DSM-5 despite rejection of this diagnosis by the American Psychiatric Association. Addiction. 2016;111(12):2110-2111.
182. Kafka MP. Hypersexual disorder: a proposed diagnosis for DSM-V. Arch Sex Behav. 2010;39(2):377-400.
183. Grant JE, Chamberlain SR. Expanding the definition of addiction: DSM-5 vs. ICD-11. CNS Spectr. 2016;21(4):300-303.
184. Corona G, Ricca V, Bandini E, et al. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med. 2009;6(5):1259-1269.
186. Goodman A. Sexual Addiction: An Integrated Approach. Madison, CT: International Universities Press; 1998.
187. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. New York, NY: Guilford; 1991.
188. Mitchell SA. Relational Concepts in Psychoanalysis: An Integration. Cambridge, MA: Harvard University Press; 1988.
189. Panksepp J, Biven L, Siegel DJ. Archaeology of Mind: Neuroevolutionary Origins of Human Emotions. New York, NY: WW Norton; 2012.
190. Wainberg ML, Muench F, Morgenstern J, et al. A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry. 2006;67(12):1968-1973.
191. Santos GM, Coffin P, Santos D, et al. Feasibility, acceptability, and tolerability of targeted naltrexone for nondependent methamphetamine-using and binge-drinking men who have sex with men. J Acquir Immune Defic Syndr. 2016;72(1):21-30.
192. Gola M, Potenza MN. Paroxetine treatment of problematic pornography use: a case series. J Behav Addict. 2016;5(3):529-532.
193. Victor EC, Sansosti AA, Bowman HC, Hariri AR. Differential patterns of amygdala and ventral striatum activation predict gender-specific changes in sexual risk behavior. J Neurosci. 2015;35(23):8896-8900.
194. Sachdeva A, Verma R. Internet gaming addiction: a technological hazard. Int J High Risk Behav Addict. 2015;4(4):e26359.
195. Park JH, Han DH, Kim BN, Cheong JH, Lee YS. Correlations among social anxiety, self-esteem, impulsivity, and game genre in patients with problematic online game playing. Psychiatry Investig. 2016;13(3):297-304.
196. Kuss DJ, Louws J, Wiers RW. Online gaming addiction? Motives predict addictive play behavior in massively multiplayer online role-playing games. Cyberpsychol Behav Soc Netw. 2012;15(9):480-485.
197. Lis E, Chiniara C, Wood MA, Biskin R, Montoro R. Psychiatrists' perceptions of World of Warcraft and other MMORPGs. Psychiatr Q. 2016;87(2):323-327.
198. Li D, Liau A, Khoo A. Examining the influence of actual-ideal self-discrepancies, depression, and escapism, on pathological gaming among massively multiplayer online adolescent gamers. Cyberpsychol Behav Soc Netw. 2011;14(9):535-539.
199. Smyth JM. Beyond self-selection in video game play: an experimental examination of the consequences of massively multiplayer online role-playing game play. Cyberpsychol Behav. 2007;10(5):717-721.
200. Kaczmarek LD, Drążkowski D. MMORPG escapism predicts decreased well-being: examination of gaming time, game realism beliefs, and online social support for offline problems. Cyberpsychol Behav Soc Netw. 2014;17(5):298-302.
201. Jansz J, Tanis M. Appeal of playing online first person shooter games. Cyberpsychol Behav. 2007;10(1):133-136.
202. Glass BD, Maddox WT, Love BC. Real-time strategy game training: emergence of a cognitive flexibility trait. PLoS One. 2013;8(8):e70350.
203. Gentile D. Pathological video-game use among youth ages 8–18: a national study. Psychol Sci. 2009;20(5):594-602.
204. Griffiths MD, Kuss DJ, Pontes HM. A brief overview of internet gaming disorder and its treatment. Aust Clin Psychol. 2016;2:1-12.
205. Stavropoulos V, Kuss DJ, Griffiths MD, Wilson P, Motti-Stefanidi F. MMORPG gaming and hostility predict Internet addiction symptoms in adolescents: an empirical multilevel longitudinal study. Addict Behav. 2017;64:294-300.
206. Ko CH, Liu GC, Hsiao S, et al. Brain activities associated with gaming urge of online gaming addiction. J Psychiatr Res. 2009;43(7):739-747.
207. Yen JY, Yeh YC, Wang PW, Liu TL, Chen YY, Ko CH. Emotional regulation in young adults with Internet gaming disorder. Int J Environ Res Public Health. 2018;15(1):30.
208. Andreassen CS, Billieux J, Griffiths MD, et al. The relationship between addictive use of social media and video games and symptoms of psychiatric disorders: a large-scale cross-sectional study. Psychol Addict Behav. 2016;30(2):252-262.
209. Gentile DA, Choo H, Liau A, et al. Pathological video game use among youths: a two-year longitudinal study. Pediatrics. 2011;127(2):e319-e329.
210. Kuss DJ, Griffiths MD, Karila L, Billieux J. Internet addiction: a systematic review of epidemiological research for the last decade.Curr Pharm Des. 2014;20(25):4026-4052.
211. Lee YH, Ko CH, Chou C. Re-visiting Internet addiction among Taiwanese students: a cross-sectional comparison of students' expectations, online gaming, and online social interaction. J Abnorm Child Psychol. 2015;43(3):589-599.
212. Forrest CJ, King DL, Delfabbro PH. Maladaptive cognitions predict changes in problematic gaming in highly-engaged adults: a 12-month longitudinal study. Addict Behav. 2017;65:125-130.
213. Whiteside SP, Lynam DR. The five factor model and impulsivity: using a structural model of personality to understand impulsivity.Pers Indiv Diff. 2001;30(4):669-689.
214. Segal B. Adolescent initiation into drug-taking behavior: comparisons over a 5-year interval. Subst Use Misuse. 1991;26(3):267-279.
215. Konkolÿ Thege B, Colman I, el-Guebaly N, et al. Social judgments of behavioral versus substance-related addictions: a population-based study. Addict Behav. 2015;42:24-31.
216. Kim NR, Hwang SS, Choi JS, et al. Characteristics and psychiatric symptoms of Internet gaming disorder among adults using self-reported DSM-5 criteria. Psychiatry Investig. 2016;13(1):58-66.
217. King DL, Delfabbro PH. The cognitive psychology of Internet gaming disorder. Clin Psychol Rev. 2014;34(4):298-308.
218. Weinstein A, Lejoyeux M. New developments on the neurobiological and pharmaco-genetic mechanisms underlying internet and videogame addiction. Am J Addict. 2015;24(2):117-125.
219. King DL, Delfabbro PH. The cognitive psychopathology of Internet gaming disorder in adolescence. J Abnorm Child Psychol. 2016;44(8):1635-1645.
220. Weinstein A, Livny A, Weizman A. New developments in brain research of internet and gaming disorder. Neurosci Biobehav Rev. 2017;75:314-330.
221. Wang R, Li M, Zhao M, et al. Internet gaming disorder: deficits in functional and structural connectivity in the ventral tegmental area-Accumbens pathway. Brain Imaging Behav. 2019;13(4):1172-1181.
222. Sharifat H, Suppiah S. Electroencephalography-detected neurophysiology of internet addiction disorder and internet gaming disorder in adolescents – a review. Med J Malaysia. 2021;76(3):401-413.
223. Metcalf O, Pammer K. Physiological arousal deficits in addicted gamers differ based on preferred game genre. Eur Addict Res. 2014;20(1):23-32.
224. Demetrovics Z, Urbán R, Nagygyörgy K, et al. Why do you play? The development of the motives for online gaming questionnaire (MOGQ). Behav Res Methods. 2011;43(3):814-825.
225. Winkler A, Dörsing B, Rief W, Shen Y, Glombiewski JA. Treatment of Internet addiction: a meta-analysis. Clin Psychol Rev. 2013;33(2):317-329.
226. Goslar M, Leibetseder M, Muench HM, Hofmann SG, Laireiter AR. Treatments for internet addiction, sex addiction and compulsive buying: a meta-analysis. J Behav Addict. 2020;9(1):14-43.
227. Liu C, Liao M, Smith DC. An empirical review of internet addiction outcome studies in China. Res Soc Work Pract. 2012;22(3):282-291.
228. Poddar S, Sayeed N, Mitra S. Internet gaming disorder: application of motivational enhancement therapy principles in treatment. Indian J Psychiatry. 2015;57(1):100-101.
229. Jäger S, Müller KW, Ruckes C, Wittig T, et al. Effects of a manualized short-term treatment of internet and computer game addiction (STICA): study protocol for a randomized controlled trial. Trials. 2012;13:43.
230. Wölfling K, Müller KW, Dreier M, Beutel ME. Short-term Treatment of Internet and Computer Game Addiction (STICA): a randomized clinical trial. J Behav Addict. 2017;6(Suppl 1):60.
231. Wölfling K, Müller KW, Dreier M, et al. Efficacy of short-term treatment of Internet computer game addiction: a randomized clinical trial. JAMA Psychiatry. 2019;76(10):1018-1025.
232. Song J, Park JH, Han DH, et al. Comparative study of the effects of bupropion and escitalopram on Internet gaming disorder. Psychiatry Clin Neurosci. 2016;70(11):527-535.
233. Han DH, Hwang JW, Renshaw PF. Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction. Exp Clin Psychopharmacol. 2010;18(4):297-304.
234. Clorado de Sa RR, Coelho S, Parmar PK, Johnstone S, Kim HS, Tavares H. A systematic review of pharmacological treatments for Internet gaming disorder. Psychiatry Investig. 2023;20(8):696-706.
235. Hebebrand J, Albayrak Ö, Adan R, et al. "Eating addiction," rather than "food addiction," better captures addictive-like eating behavior. Neurosci Biobehav Rev. 2014;47:295-306.
236. Markus CR, Rogers PJ, Brouns F, Schepers R. Eating dependence and weight gain: no human evidence for a "sugar-addiction" model of overweight. Appetite. 2017;114:64-72.
237. Greenberg D, St Peter JV. Sugars and sweet taste: addictive or rewarding? Int J Environ Res Public Health. 2021;18(18):9791.
238. Stice E, Marti CN, Rohde P. Prevalence, incidence, impairment, and course of the proposed DSM-5 eating disorder diagnoses in an 8-year prospective community study of young women. J Abnorm Psychol. 2013;122(2):445-457.
239. Udo T, Grilo CM. Prevalence and correlates of DSM-5-defined eating disorders in a nationally representative sample of U.S. adults.Biol Psychiatry. 2018;84(5):345-354.
240. Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization world mental health surveys. Biol Psychiatry. 2013;73(9):904-914.
241. Marques L, Alegria M, Becker AE, et al. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across U.S. ethnic groups: implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord. 2011;44(5):412-420.
242. Cattivelli R, Pietrabissa G, Ceccarini M, et al. ACTonFOOD: opportunities of ACT to address food addiction. Front Psychol. 2015;6:396.
243. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348-358.
244. Allison KC, Grilo CM, Masheb RM, Stunkard AJ. Binge eating disorder and night eating syndrome: a comparative study of disordered eating. J Consult Clin Psychol. 2005;73(6):1107-1115.
245. Blomquist KK, Milsom VA, Barnes RD, et al. Metabolic syndrome in obese men and women with binge eating disorder: developmental trajectories of eating and weight-related behaviors. Compr Psychiatry. 2012;53(7):1021-1027.
246. Allen KL, Byrne SM, Oddy WH, Crosby RD. DSM-IV-TR and DSM-5 eating disorders in adolescents: prevalence, stability, and psychosocial correlates in a population-based sample of male and female adolescents. J Abnorm Psychol. 2013;122(3):720-732.
247. Ackard DM, Fulkerson JA, Neumark-Sztainer D. Stability of eating disorder diagnostic classifications in adolescents: five-year longitudinal findings from a population-based study. Eat Disord. 2011;19(4):308-322.
248. Whisman MA, Dementyeva A, Baucom DH, Bulik CM. Marital functioning and binge eating disorder in married women. Int J Eat Disord. 2012;45(3):385-389.
249. Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003;60(11):1109-1116.
250. Amianto F, Ottone L, Abbate Daga G, Fassino S. Binge-eating disorder diagnosis and treatment: a recap in front of DSM-5. BMC Psychiatry. 2015;15:70.
251. Brownley KA, Peat CM, La Via M, Bulik CM. Pharmacological approaches to the management of binge eating disorder. Drugs. 2015;75(1):9-32.
252. Joyner MA, Gearhardt AN, White MA. Food craving as a mediator between addictive-like eating and problematic eating outcomes.Eat Behav. 2015;19:98-101.
253. Mason AE, Laraia B, Daubenmier J, et al. Putting the brakes on the "drive to eat:" pilot effects of naltrexone and reward-based eating on food cravings among obese women. Eat Behav. 2015;19:53-56.
254. Schneider E, Higgs S, Dourish CT. Lisdexamfetamine and binge-eating disorder: a systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. Eur Neuropsychopharmacol. 2021;53:49-78.
255. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association; Washington, DC: 2000.
256. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. American Psychiatric Association; Washington, DC: 2000.
257. Neumark-Sztainer D, Story M, Hannan P J, Perry C L, Irving LM. Weight-related concerns and behaviors among overweight and nonoverweight adolescents: implications for preventing weight-related disorders. Arch Pediat Adoles Med. 2002;156:171-178.
258. He J, Cai Z, Fan X. Prevalence of binge and loss of control eating among children and adolescents with overweight and obesity: an exploratory meta-analysis. Int J Eat Disord. 2017;50(2):91-103.
259. Grilo CM, Crosby RD, Masheb RM, et al. Overvaluation of shape and weight in binge eating disorder, bulimia nervosa, and sub-threshold bulimia nervosa. Behav Res Ther. 2009;47(8):692-696.
260. Goracci A, di Volo S, Casamassima F, Bolognesi S, Benbow J, Fagiolini A. Pharmacotherapy of binge-eating disorder: a review. J Addict Med. 2015;9(1):1-19.
261. Reas DL, Grilo CM. Pharmacological treatment of binge eating disorder: update review and synthesis. Expert Opin Pharmacother. 2015;16(10):1463-1478.
262. Grilo CM, Hrabosky JI, White MA, et al. Overvaluation of shape and weight in binge eating disorder and overweight controls: refinement of a diagnostic construct. J Abnorm Psychol. 2008;117(2):414-419.
263. Ricca V, Castellini G, Mannucci E, et al. Comparison of individual and group cognitive behavioral therapy for binge eating disorder: a randomized, three-year follow-up study. Appetite. 2010;55(3):656-665.
264. Wilfley DE, Welch RR, Stein RI, et al. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. Arch Gen Psychiatry. 2002;59(8):713-721.
265. Tasca G, Ritchie K, Conrad G, et al. Attachment scales predict outcome in a randomized controlled trial of two group therapies for binge eating disorder: an aptitude by treatment interaction. Psychother Res. 2006;16(1):106-121.
266. Grammer AC, Monterubio GE, D'Adamo L, et al. Evaluation of a combined, online intervention for binge-type eating disorders and high body weight in young adults. Eat Behav. 2023;50:101789.
267. Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord. 2012;45(2):281-289.
268. Safer DL, Adler S, Dalai SS, et al. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord. 2020;53(2):266-277.
269. Lexicomp Online. Available at https://online.lexi.com. Last accessed April 3, 2024.
270. Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10(1):14-30.
271. Barrea L, Pugliese G, Muscogiuri G, Laudisio D, Colao A, Savastano S. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva Endocrinol. 2020;45(2):127-137.
272. Farci AM, Piras S, Murgia M, et al. Disulfiram for binge eating disorder: an open trail. Eat Behav. 2015;16:84-87.
273. Burgess EE, Sylvester MD, Morse KE, et al. Effects of transcranial direct current stimulation (tDCS) on binge eating disorder. Int J Eat Disord. 2016;49(10):930-936.
274. Hudson JI, Lalonde JK, Coit CE, et al. Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. Am J Clin Nutr. 2010;91(6):1568-1573.
275. Luiz LB, Brito CL, Debon LM, et al. Variation of binge eating one year after Roux-en-Y gastric bypass and its relationship with excess weight loss. PLoS One. 2016;11(2):e0167577.
276. Val-Laillet D, Aarts E, Weber B, et al. Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity. Neuroimage Clin. 2015;8:1-31.
277. Hertz P, Addaad M, Ronel N. Attachment styles and changes among women members of overeaters anonymous who have recovered from binge-eating disorder. Health Soc Work. 2012;37(2):110-122.
278. Hernandez-Hons A, Woolley SR. Women's experiences with emotional eating and related attachment and sociocultural processes.J Marital Fam Ther. 2012;38(4):589-603.
280. Granero R, Fernández-Aranda F, Mestre-Bach G, et al. Compulsive buying behavior: clinical comparison with other behavioral addictions. Front Psychol. 2016;7:914.
281. Karim R, Chaudhri P. Behavioral addictions: an overview. J Psychoactive Drugs. 2012;44(1):5-17.
282. Hussain N, Guanci N, Raza M, et al. Shopping addiction. In: Ascher MS, Levounis P (eds). The Behavioral Addictions. Arlington, VA: American Psychiatric Publishing; 2015.
283. Maraz A, van den Brink W, Demetrovics Z. Prevalence and construct validity of compulsive buying disorder in shopping mall visitors. Psychiatry Res. 2015;228(3):918-924.
284. McElroy S, Keck PE Jr, Pope HG Jr, Smith JM, Strakowski SM. Compulsive buying: a report of 20 cases. J Clin Psychiatry. 1994;55(6):242-248.
285. Zander H, Claes L, Voth EM, de Zwaan M, Müller A. Impulsive behaviors in patients with pathological buying. J Behav Addict. 2016;5(3):457-464.
286. Weinstein A, Mezig H, Mizrachi S, Lejoyeux M. A study investigating the association between compulsive buying with measures of anxiety and obsessive-compulsive behavior among internet shoppers. Compr Psychiatry. 2015;57:46-50.
287. McQueen P, Moulding R, Kyrios M. Experimental evidence for the influence of cognitions on compulsive buying. J Behav Ther Exp Psychiatry. 2014;45(4):496-501.
288. Roberts JA, Manolis C, Pullig C. Contingent self-esteem, self-presentational concerns, and compulsive buying. Psychol Mark. 2014;31(2):147-160.
289. Hague B, Hall J, Kellett S. Treatments for compulsive buying: a systematic review of the quality, effectiveness and progression of the outcome evidence. J Behav Addict. 2016;5(3):379-394.
290. Granero R, Fernández-Aranda F, Baño M, et al. Compulsive buying disorder clustering based on sex, age, onset and personality traits. Compr Psychiatry. 2016;68:1-10.
291. Billieux J, Lagrange G, Van der Linden M, Lançon C, Adida M, Jeanningros R. Investigation of impulsivity in a sample of treatment-seeking pathological gamblers: a multidimensional perspective. Psychiatry Res. 2012;198(2)291-296.
292. Lorains FK, Stout JC, Bradshaw JL, Dowling NA, Enticott PG. Self-reported impulsivity and inhibitory control in problem gamblers.J Clin Exp Neuropsychol. 2014;36(2):144-157.
293. Lawrence LM, Ciorciari J, Kyrios M. Relationships that compulsive buying has with addiction, obsessive-compulsiveness, hoarding, and depression. Compr Psychiatry. 2014;55(5):1137-1145.
294. Trotzke P, Starcke K, Müller A, Brand M. Pathological buying online as a specific form of Internet addiction: a model-based experimental investigation. PLoS One. 2015;10(10):e0140296.
295. Hartston H. The case for compulsive shopping as an addiction. J Psychoactive Drugs. 2012;44(1):64-67.
296. Olsen CM. Natural rewards, neuroplasticity, and non-drug addictions. Neuropharmacology. 2011;61(7):1109-1122.
297. Franken IHA, Muris P, Georgieva I. Gray's model of personality and addiction. Addict Behav. 2006;31(3):399-403.
298. Davenport K, Houston JE, Griffiths MD. Excessive eating and compulsive buying behaviours in women: an empirical pilot study examining reward sensitivity, anxiety, impulsivity, self-esteem and social desirability. Int J Ment Health Addict. 2012;10(4):474-489.
299. Lawrence LM, Ciorciari J, Kyrios M. Cognitive processes associated with compulsive buying behaviours and related EEG coherence. Psychiatry Res. 2014;221(1):97-103.
300. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1987.
301. Monahan P, Black D, Gabel J. Reliability and validity of a scale to measure change in persons with compulsive buying. Psychiatry Res. 1996;64(1):59-67.
302. Vasiliu O. Therapeutic management of buying/shopping disorder: a systematic literature review and evidence-based recommendations. Front Psychiatry. 2022;13:1047280.
303. Leite PL, Filomensky TZ, Black DW, Silva AC. Validity and reliability of the Brazilian version of Yale-Brown obsessive compulsive scale-shopping version (YBOCS-SV). Compr Psychiatry. 2014;55(6):1462-1466.
304. Firth N, Barkham M, Kellett S. The clinical effectiveness of stepped care systems for depression in working age adults: a systematic review. J Affect Disord. 2015;170:119-130.
305. Ridgeway N, Kukar-Kinney M, Monroe K. The measurement of compulsive buying and its application to Internet buyers. In: Müller A, Mitchell J (eds). Compulsive Buying: Clinical Foundations and Treatment. New York, NY: Routledge; 2011: 51-62.
306. Müller A, Laskowski NM, Thomas TA, et al. Update on treatment studies for compulsive buying-shopping disorder: a systematic review. J Behav Addict. 2023;12(3):631-651.
308. Johnson J, El-Alfy AT. Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania.J Adv Res. 2016;7(2):169-184.
309. King RA, Zohar AH, Ratzoni G, et al. An epidemiological study of trichotillomania in Israeli adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(9):1212-1215.
310. Christenson GA. Trichotillomania: from prevalence to comorbidity. Psychiatric Times. 1995;12(9):44-48.
312. Woods DW, Flessner CA, Franklin ME, et al. The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization. J Clin Psychiatry. 2006;67(12):1877-1888.
313. Duke DC, Keeley ML, Geffken GR, Storch EA. Trichotillomania: a current review. Clin Psychol Rev. 2010;30(2):181-193.
314. Cohen LJ, Stein DJ, Simeon D, et al. Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. J Clin Psychiatry. 1995;56(7):319-326.
315. Diefenbach GJ, Tolin DF, Hannan S, Crocetto J, Worhunsky P. Trichotillomania: impact on psychosocial functioning and quality of life. Behav Res Ther. 2005;43(7):869-884.
316. Odlaug BL, Kim SW, Grant JE. Quality of life and clinical severity in pathological skin picking and trichotillomania. J Anxiety Disord. 2010;24(8):823-829.
317. Grant JE, Odlaug BL. Clinical characteristics of trichotillomania with trichophagia. Compr Psychiatry. 2008;49(6):579-584.
318. Lewin AB, Piacentini J, Flessner CA, et al. Depression, anxiety, and functional impairment in children with trichotillomania. Depress Anxiety. 2009;26(6):521-527.
319. Christenson GA, Mansueto CS. Trichotillomania: descriptive characteristics and phenomenology. In: Stein DJ, Christianson GA, Hollander E (eds). Trichotillomania. Washington, DC: American Psychiatric Press; 1999.
320. Ferrão YA, Miguel E, Stein DJ. Tourette's syndrome, trichotillomania, and obsessive-compulsive disorder: how closely are they related? Psychiatry Res. 2009;170(1):32-42.
321. Chamberlain SR, Odlaug BL, Boulougouris V, Fineberg NA, Grant JE. Trichotillomania: neurobiology and treatment. Neurosci Biobehav Rev. 2009;33(6):831-842.
322. Roberts S, O'Connor K, Bélanger C. Emotion regulation and other psychological models for body-focused repetitive behaviors. Clin Psychol Rev. 2013;33(6):745-762.
323. Chamberlain SR, Hampshire A, Menzies LA, et al. Reduced brain white matter integrity in trichotillomania: a diffusion tensor imaging study. Arch Gen Psychiatry. 2010;67(9):965-971.
324. Roos A, Fouche JP, Stein DJ, Lochner C. Structural brain network connectivity in trichotillomania (hair-pulling disorder). Brain Imaging Behav. 2023;17(4):395-402.
325. Grant JE, Bethlehem RA, Chamberlain SR, et al. Neurobiology of subtypes of trichotillomania and skin picking disorder. CNS Spectr. 2023;28(1):98-103.
326. Rauch SL, Wright CI, Savage CR, et al. Brain activation during implicit sequence learning in individuals with trichotillomania. Psychiatry Res. 2007;154(3):233-240.
327. Grant JE, Redden SA, Leppink EW, Chamberlain SR. Trichotillomania and co-occurring anxiety. Compr Psychiatry. 2017;72:1-5.
328. Rogers K, Banis M, Falkenstein MJ, et al. Stepped care in the treatment of trichotillomania. J Consult Clin Psychology. 2014;82(2):361-367.
329. Rehm I, Moulding R, Nedeljkovic M. Psychological treatments for trichotillomania: update and future directions. Australas Psychiatry. 2015;23(4):365-368.
330. Keuthen NJ, Rothbaum BO, Fama J, et al. DBT-enhanced cognitive-behavioral treatment for trichotillomania: a randomized controlled trial. J Behav Addict. 2012;1(3):106-114.
331. Shareh H. A preliminary investigation of metacognitive therapy and habit reversal as a treatment for trichotillomania. Behav Cogn Psychother. 2018;46(1):1-20.
332. Rothbart R, Amos T, Siegfried N, et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2013;8(11):CD007662.
333. Hoffman J, Williams T, Rothbart R, et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021;(9):CD007662.
334. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756-763.
335. Lee DK, Lipner SR. The potential of N-acetylcysteine for treatment of trichotillomania, excoriation disorder, onychophagia, and onchotillomania: an updated literature review. Int J Environ Res Public Health. 2022;19(11):6370.
336. Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010;71(10):1336-1343.
337. Grant JE, Odlaug BL, Chamberlain SR, Kim SW. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology (Berl). 2011;218(3):493-502.
338. Grant JE, Valle S, Chesivoir E, Ehsan D. Tetrahydrocannabinol fails to reduce hair pulling or skin picking: results of a double-blind, placebo-controlled study of dronabinol. Int Clin Psychopharmacol. 2022;37(1):14-20.
339. Grant JE, Odlaug BL, Schreiber LR, Chamberlain SR, Kim SW. Memantine reduces stealing behavior and impulsivity in kleptomania: a pilot study. Int Clin Psychopharmacol. 2013;28(2):106-111.
340. Grant JE. Understanding and treating kleptomania: new models and new treatments. Isr J Psychiatry Relat Sci. 2006;43(2):81-87.
341. Zerbo E, Deringer E. Kleptomania. In: Ascher MS, Levounis P (eds). The Behavioral Addictions. Washington, DC: American Psychiatric Publishing; 2015.
342. Grant JE, Odlaug BL, Kim SW. Kleptomania: clinical characteristics and relationship to substance use disorders. Am J Drug Alcohol Abuse. 2010;36(5):291-295.
343. Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry. 2005;162(11):2184-2188.
344. Grant JE, Odlaug BL, Davis AA, Kim SW. Legal consequences of kleptomania. Psychiatr Q. 2009;80(4):251-259.
345. Sarasalo E, Bergman B, Toth J. Theft behavior and its consequences among kleptomaniacs and shoplifters—a comparative study. Forensic Sci Int. 1997;86(3):193-205.
346. Odlaug BL, Grant JE, Kim SW. Suicide attempts in 107 adolescents and adults with kleptomania. Arch Suicide Res. 2012;16(4):348-359.
347. Figee M, Pattij T, Willuhn I, et al. Compulsivity in obsessive-compulsive disorder and addictions. Eur Neuropsychopharmacol. 2016;26(5):856-868.
348. Mouaffak F, Leite C, Hamzaoui S, et al. Naltrexone in the treatment of broadly defined behavioral addictions: a review and meta-analysis of randomized controlled trials. Eur Addict Res. 2017;23(4):204-210.
349. Grant JE, Kim SW. Stop Me Because I Can't Stop Myself: Taking Control of Impulsive Behavior. New York, NY: McGraw-Hill; 2003.
350. Saluja B, Chan LG, Dhaval D. Kleptomania: a case series. Singapore Med J. 2014;55(12):e207-e209.
351. Grant JE, Potenza MN. Gender-related differences in individuals seeking treatment for kleptomania. CNS Spectr. 2008;13(3):235-245.
352. Christianini AR, Conti MA, Hearst N, Cordás TA, de Abreu CN, Tavares H. Treating kleptomania: cross-cultural adaptation of the Kleptomania Symptom Assessment Scale and assessment of an outpatient program. Compr Psychiatry. 2015;56:289-294.
353. Grant JE, Kim SW, Odlaug BL. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of kleptomania. Biol Psychiatry. 2009;65(7):600-606.
354. Koran L, Aboujaoude E, Solvason B, Gamel NN, Smith EH. Escitalopram for compulsive buying disorder: a double-blind discontinuation study. J Clin Psychopharmacol. 2007;27(2):225-227.
355. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595.
356. Drew DS, Muhammed K, Baig F, et al. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. Brain. 2020;143(8):2502-2518.
357. Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. 2017;16(3):238-250.
358. Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011;34(2):66-70.
359. Gaboriau L, Victorri-Vigneau C, Gérardin M, Allain-Veyrac G, Jolliet-Evin P, Grall-Bronnec M. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict Behav. 2014;39(3):562-565.
360. Scavone C, Stelitano B, Rafaniello C, Rossi F, Sportiello L, Capuano A. Drug-induced pathological gambling: an analysis of Italian spontaneous reporting system. J Gambl Stud. 2020;36(1):85-96.
361. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006;30(1):1-23.
362. Scheltema Beduin A, de Haan L. Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull. 2010;43(3):45-81.
Part 10 of 14 · Chapter 1 of 14
Mention of commercial products does not indicate endorsement.